Clinical Trial Update: Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 trial of Tarceva (erlotinib) for recurrent/residual glioblastoma multiforme and anaplastic astrocytoma; the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Northwell Health | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-02-10